There has been new momentum at the highest political levels to put plans into place that will make the most use of the recent science showing ART itself both saves lives and stops HIV from spreading. International funding, however, remains largely stagnant across the board and will need to be increased to achieve the goals of saving more lives through treatment, while dramatically reducing HIV transmission.
Encompassing eleven countries and slated for further expansion across the Asia Pacific region, the Trans-Pacific Partnership Agreement (TPP) is a regional trade agreement that will set the standard for 21st-century trade agreements going forward.
Severe malaria has traditionally been treated with quinine. Today, the latest scientific evidence clearly shows that many more children’s lives can be saved by switching treatment from quinine to a more effective drug, artesunate.
But just as important gains are beginning to show their promise for patients, a stagnation in donor funding, coupled with trade policies that will create serious additional barriers to accessing affordable generic medicines, are dealing HIV/AIDS treatment a double blow.
In late 2009, the World Health Organization (WHO) issued new international recommendations concerning the fight against HIV/AIDS. WHO advocates treating more patients by starting antiretroviral therapy at an earlier stage and using higher quality drugs. These measures will result in an increase in the number of infected people eligible for treatment. While beneficial, the new recommendations pose many challenges and come amid an unfavorable global environment.